A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
|Articles|October 30, 2020
Influenza Coinfection with COVID-19: NIH Treatment Considerations
Author(s)Grace Halsey
Recent NIH COVID-19 guideline updates include evidence-based considerations for treatment of patients hospitalized with flu and COVID-19 coinfection.
Advertisement
The National Institutes of Health on in late October 2020
Advertisement
Related to this article
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
The organizations challenge a presidential executive order narrowing routine childhood vaccine recommendations and urging vaccines to be given separately.
FDA acceptance starts review of clesrovimab for second-season RSV prevention in high-risk children younger than 2 years.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Advertisement
Advertisement
Trending on Patient Care Online
1
Combating Prostate Cancer Misconceptions in Primary Care: An Expert Discussion
2
ASH Raises Ferritin Thresholds for Diagnosing Iron Deficiency
3
Endocrine Society Obesity Statement Calls for Goals Beyond Weight Loss
4
FDA Approves Finerenone for CKD Associated With Type 1 Diabetes
5